Sparsentan — Dosing in CKD & Dialysis

Sparsentan (Dual Endothelin Angiotensin Receptor Antagonist): renal dosing adjustments, dialyzability (Dialysis is unlikely to be effective (more than 99% protein-bound; Filspari label sections 10 and 12.3)), and renal-relevant safety risk for CKD and dialysis patients. Educational reference for nep

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.